Imvaria

Executive Summary

Imvaria is a pioneering software-as-medical-device (SaMD) company leveraging AI to develop non-invasive digital biomarkers for interstitial lung diseases (ILD), with an initial focus on idiopathic pulmonary fibrosis (IPF). The company’s lead product, Fibresolve, is already FDA-authorized for analyzing medical imaging to aid in diagnosis, reducing the need for invasive biopsies. By transforming clinical decision-making through advanced AI analysis, Imvaria addresses a significant unmet need in ILD diagnosis, where early and accurate detection is critical. The company, headquartered in San Francisco, is privately held and operates in the diagnostics sector. With its AI-driven approach and regulatory foothold, Imvaria is well-positioned to expand its platform into additional indications and capture market share in the growing digital diagnostics space. The company’s technology has the potential to improve patient outcomes and reduce healthcare costs by enabling earlier, non-invasive diagnosis of complex lung diseases.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance Expansion for Additional ILD Subtypes70% success
• Q3 2026Publication of Pivotal Clinical Study Results Supporting Expanded Use65% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Diagnostic Company50% success